C9 Polyclonal Antibody

    • Catalog No.:YT0571
    • Applications:WB;ELISA
    • Reactivity:Human;Rat;Mouse;
      • Target:
      • C9
      • Fields:
      • >>Complement and coagulation cascades;>>Prion disease;>>Amoebiasis;>>Coronavirus disease - COVID-19;>>Systemic lupus erythematosus
      • Gene Name:
      • C9
      • Protein Name:
      • Complement component C9
      • Human Gene Id:
      • 735
      • Human Swiss Prot No:
      • P02748
      • Mouse Swiss Prot No:
      • P06683
      • Immunogen:
      • The antiserum was produced against synthesized peptide derived from human C9. AA range:181-230
      • Specificity:
      • C9 Polyclonal Antibody detects endogenous levels of C9 protein.
      • Formulation:
      • Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
      • Source:
      • Polyclonal, Rabbit,IgG
      • Dilution:
      • WB 1:500 - 1:2000. ELISA: 1:40000. Not yet tested in other applications.
      • Purification:
      • The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
      • Concentration:
      • 1 mg/ml
      • Storage Stability:
      • -15°C to -25°C/1 year(Do not lower than -25°C)
      • Other Name:
      • C9;Complement component C9
      • Observed Band(KD):
      • 70kD
      • Background:
      • This gene encodes the final component of the complement system. It participates in the formation of the Membrane Attack Complex (MAC). The MAC assembles on bacterial membranes to form a pore, permitting disruption of bacterial membrane organization. Mutations in this gene cause component C9 deficiency. [provided by RefSeq, Feb 2009],
      • Function:
      • disease:Defects in C9 are a cause of component C9 deficiency (C9D) [MIM:120940]. Patients with C9D suffer from recurrent bacterial infections, predominantly from Neisseria meningitidis.,function:C9 is the final component of the complement system to be added in the assembly of the membrane attack complex. It is able to enter lipid bilayers, forming transmembrane channels.,online information:C9 mutation db,PTM:Thrombin cleaves factor C9 to produce C9a and C9b.,similarity:Belongs to the complement C6/C7/C8/C9 family.,similarity:Contains 1 EGF-like domain.,similarity:Contains 1 LDL-receptor class A domain.,similarity:Contains 1 MACPF domain.,similarity:Contains 1 TSP type-1 domain.,
      • Subcellular Location:
      • Secreted . Target cell membrane ; Multi-pass membrane protein . Secreted as soluble monomer. Oligomerizes at target membranes, forming a pre-pore. A conformation change then leads to the formation of a 100 Angstrom diameter pore. .
      • Expression:
      • Plasma (at protein level).
      • Products Images
      • Western Blot analysis of various cells using C9 Polyclonal Antibody
      • Western Blot analysis of COLO205 cells using C9 Polyclonal Antibody
      • Western blot analysis of lysates from COLO cells, using C9 Antibody. The lane on the right is blocked with the synthesized peptide.